Eidos Therapeutics Inc (NASDAQ:EIDX) has been given a consensus recommendation of “Buy” by the eight brokerages that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $55.83.
A number of equities research analysts recently issued reports on EIDX shares. ValuEngine cut Eidos Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd. Zacks Investment Research upgraded Eidos Therapeutics from a “hold” rating to a “buy” rating and set a $52.00 price target on the stock in a research report on Monday, November 18th. Barclays cut Eidos Therapeutics from an “overweight” rating to an “equal weight” rating and upped their price target for the company from $37.00 to $45.00 in a research report on Friday, November 1st. BTIG Research set a $56.00 price target on Eidos Therapeutics and gave the company a “buy” rating in a research report on Tuesday, October 15th. Finally, Piper Jaffray Companies upped their price target on Eidos Therapeutics from $55.00 to $75.00 and gave the company an “overweight” rating in a research report on Tuesday, November 19th.
In other news, insider Uma Sinha sold 2,500 shares of the company’s stock in a transaction dated Wednesday, September 25th. The stock was sold at an average price of $38.41, for a total transaction of $96,025.00. Also, CFO Christine Siu sold 35,000 shares of the company’s stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $57.48, for a total value of $2,011,800.00. Over the last quarter, insiders have sold 112,500 shares of company stock worth $6,273,275. Company insiders own 70.10% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the company. Bank of Montreal Can grew its holdings in shares of Eidos Therapeutics by 151.8% during the second quarter. Bank of Montreal Can now owns 1,385 shares of the company’s stock worth $43,000 after purchasing an additional 835 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of Eidos Therapeutics during the second quarter worth about $125,000. Metropolitan Life Insurance Co NY purchased a new position in shares of Eidos Therapeutics during the first quarter worth about $143,000. Strs Ohio grew its holdings in shares of Eidos Therapeutics by 457.1% during the second quarter. Strs Ohio now owns 11,700 shares of the company’s stock worth $363,000 after purchasing an additional 9,600 shares in the last quarter. Finally, Swiss National Bank purchased a new position in shares of Eidos Therapeutics during the second quarter worth about $426,000. Hedge funds and other institutional investors own 30.46% of the company’s stock.
Eidos Therapeutics stock traded down $0.03 during midday trading on Friday, reaching $65.57. The stock had a trading volume of 164,066 shares, compared to its average volume of 161,676. Eidos Therapeutics has a 12 month low of $11.15 and a 12 month high of $66.30. The firm’s 50-day moving average price is $51.07 and its 200 day moving average price is $40.14. The firm has a market capitalization of $2.24 billion, a PE ratio of -35.25 and a beta of -0.86. The company has a quick ratio of 17.00, a current ratio of 17.00 and a debt-to-equity ratio of 0.03.
Eidos Therapeutics (NASDAQ:EIDX) last announced its quarterly earnings data on Thursday, October 31st. The company reported $0.18 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.48. The firm had revenue of $26.69 million during the quarter. Equities research analysts expect that Eidos Therapeutics will post -1.07 EPS for the current year.
About Eidos Therapeutics
Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.
Featured Article: How a Strangle Strategy is different from a Straddle Strategy
Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.